- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06631989
Tutkimus WSD0922-FU:n tehon ja turvallisuuden arvioimiseksi potilailla, joilla on EGFRm+ edennyt ei-pienisoluinen keuhkosyöpä
Vaiheen I/II monikeskus, avoin, yksihaarainen tutkimus WSD0922-FU:n turvallisuuden, siedettävyyden, farmakokinetiikka ja tehon arvioimiseksi edenneen ei-pienisoluisen keuhkosyövän hoidossa
This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
WSD0922-FU is a potent reversible inhibitor of both the single EGFRm+ and dual EGFRm+/C797S+ receptor forms of EGFR with selectivity margin over wild-type EGFR. This study aims to explore the safety, tolerability, pharmacokinetic characteristics and efficacy of WSD0922-FU in patients with non-small cell lung cancer (NSCLC) with C797S mutation after first-line third-generation EGFR-TKI resistance.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Anhui
-
Hefei, Anhui, Kiina, 230031
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Guangdong
-
Guangzhou, Guangdong, Kiina, 510062
- The First Affiliated Hospital, Sun Yat-sen University
-
-
Henan
-
Zhengzhou, Henan, Kiina, 450000
- He'nan Cancer Hospital
-
-
Shandong
-
Jinan, Shandong, Kiina, 250117
- Shandong Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kiina, 200433
- Shanghai Pulmonary Hospital
-
Shanghai, Shanghai Municipality, Kiina, 200030
- Shanghai Chest Hospital
-
Shanghai, Shanghai Municipality, Kiina, 200123
- Shanghai East Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Kiina, 610041
- Sichuan Provincial Cancer Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kiina, 300202
- Tianjin Medical University Cancer Institute and Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kiina, 310006
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Taizhou, Zhejiang, Kiina, 317000
- Taizhou Hospital of Zhejiang Province
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age 18-75 years old (including the threshold value), gender is not limited;
- Locally advanced or metastatic NSCLC confirmed by pathology;
- Patients who have been genetically tested to carry EGFR sensitive mutations;
- Blood samples must be provided for testing and must be taken during or after disease progression following the last EGFR TKI inhibitor treatment;
- Must have a minimum life expectancy of >= 3 months;
- At least one measurable tumor lesion according to RECIST version 1.1; Previous radiotherapy-treated lesions cannot be used as target lesions unless imaging studies show clear progression of the lesions.
- Physical Status (ECOG PS) score was 0-1;
- Have full organ function;
- Eligible patients (male and female) who are fertile must agree to use a reliable contraceptive method ;
- Subjects are required to give informed consent to this study before the experiment and sign a written informed consent voluntarily.
Exclusion Criteria:
- Received chemotherapy, radiotherapy, biological therapy, targeted therapy, endocrine therapy, immunotherapy, or other anti-tumor drug treatments within 4 weeks before the first administration of the study drug.
- Have previously received more than one EGFR-TKI inhibitor;
- Received other unlisted clinical study drugs or treatments within 4 weeks before the first administration.
- Received major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks before the first administration, or require elective surgery during the trial period.
- Used strong CYP3A4 inhibitors or strong CYP3A4 inducers within 7 days before the first use of the study drug.
- Known active brain metastasis or progression evidence.
- Other primary malignant tumors within 2 years before the first administration of the study drug.
- Adverse reactions from previous anti-tumor treatments have not recovered to NCI-CTCAE v5.0 grade ≤1 (except for toxicities judged by the researcher to have no safety risks, such as hair loss, grade 2 peripheral neurotoxicity, and stable thyroid function after hormone replacement therapy).
- Skin/pressure ulcers, chronic leg ulcers, known active gastric ulcers, or non-healing wounds.
- History of severe allergies, or allergies to any active or inactive ingredients of the study drug;
- Severe infections requiring intravenous antibiotic infusion or hospitalization at the time of screening; or uncontrollable active infections within 4 weeks before administration;
- Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema);
- Human immunodeficiency virus (HIV) (HIV1/2 antibody) positive, syphilis spirochete antibody positive .
- Patients with interstitial lung disease.
- History of severe cardiovascular diseases.
- Unable to orally swallow medication, or there is a condition that significantly affects gastrointestinal absorption as judged by the researcher;
- Clinical intervention is required for pleural effusion, ascites (excluding subjects who do not need drainage and have been stable for more than 2 weeks after drainage).
- Known alcohol or drug dependence.
- Mental disorders or poor compliance;
- Pregnant or lactating women;
- The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Dose escalation (WSD0922-FU)
Patients receive WSD0922-FU PO QD on C0D1 to C0D3, then BID on C1D1 to C1D21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study. |
Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI Drug: WSD0922-FU Given PO
Muut nimet:
|
|
Kokeellinen: Dose expansion (WSD0922-FU)
Patients receive WSD0922-FU PO BID on C1D1 to C1D21 using dosage selected from Dose escalation. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study. |
Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI Drug: WSD0922-FU Given PO
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
ORR by IRC
Aikaikkuna: every 6 weeks, up to 1 year
|
proportion of patients with a best overall response of complete response or partial response |
every 6 weeks, up to 1 year
|
|
PartA: To evaluate the safety of WSD0922-FU in patients with NSCLC
Aikaikkuna: 8 months
|
Safety (incidence and severity of adverse events [AE]) |
8 months
|
|
PartA: To evaluate the tolerability of WSD0922-FU in patients with NSCLC
Aikaikkuna: 8 months
|
Incidence and quantity of dose-limiting toxicity (DLT) |
8 months
|
|
PartA: To evaluate the Maximum Tolerated Dose (MTD) of WSD0922-FU in patients with NSCLC
Aikaikkuna: 8 months
|
Incidence of Dose-Limiting Toxicities (DLTs) |
8 months
|
|
PartA: Recommended Phase II Dose (RP2D) of WSD0922-FU in patients with NSCLC
Aikaikkuna: 8 months
|
Recommended Phase II Dose (RP2D) |
8 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
To evaluate the safety of WSD0922-FU in patients with advanced non-small cell lung cancer
Aikaikkuna: 12 months
|
Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (TRAEs) |
12 months
|
|
PK exposure parameter: Maximum Plasma Concentration (Cmax)
Aikaikkuna: 12 months
|
Maximum Plasma Concentration (Cmax) |
12 months
|
|
PK exposure parameter: Time To Maximum Plasma Concentration (Tmax)
Aikaikkuna: 12 months
|
Time To Maximum Plasma Concentration (Tmax) |
12 months
|
|
PK exposure parameter: Area Under The Plasma Concentration-Time Curve From Time Zero To Time With Last Measurable Concentration (AUC0-t)
Aikaikkuna: 12 months
|
Area Under The Plasma Concentration-Time Curve From Time Zero To Time With Last Measurable Concentration (AUC0-t) |
12 months
|
|
PK exposure parameter: Area Under The Plasma Concentration-Time Curve From Time Zero To Infinity (AUC0-∞)
Aikaikkuna: 12 months
|
Area Under The Plasma Concentration-Time Curve From Time Zero To Infinity (AUC0-∞) |
12 months
|
|
PK exposure parameter: Terminal Elimination Half-Life (t½)
Aikaikkuna: 12 months
|
Terminal Elimination Half-Life (t½) |
12 months
|
|
PK exposure parameter: Apparent Terminal Elimination Rate Constant (λz)
Aikaikkuna: 12 months
|
Apparent Terminal Elimination Rate Constant (λz) |
12 months
|
|
PK exposure parameter: Apparent Clearance (CL)
Aikaikkuna: 12 months
|
Apparent Clearance (CL) |
12 months
|
|
PK exposure parameter: Apparent volume of distribution (Vd)
Aikaikkuna: 12 months
|
Apparent volume of distribution (Vd) |
12 months
|
|
PK exposure parameter: Mean Residence Time (MRT)
Aikaikkuna: 12 months
|
Mean Residence Time (MRT) |
12 months
|
|
Steady state pharmacokinetic parameter: Area Under the Steady-State Concentration-Time Curve(AUCss)
Aikaikkuna: 12 months
|
Area Under the Steady-State Concentration-Time Curve(AUCss) |
12 months
|
|
Steady state pharmacokinetic parameter: Area Under the Steady-State Concentration-Time Curve from 0 to Infinity(AUC0-∞,ss)
Aikaikkuna: 12 months
|
Area Under the Steady-State Concentration-Time Curve from 0 to Infinity(AUC0-∞,ss) |
12 months
|
|
Steady state pharmacokinetic parameter: Area Under the Steady-State Concentration-Time Curve from 0 to Time t (AUC0-t,ss)
Aikaikkuna: 12 months
|
Area Under the Steady-State Concentration-Time Curve from 0 to Time t (AUC0-t,ss) |
12 months
|
|
Steady state pharmacokinetic parameter: Average Steady-State Concentration(Cav)
Aikaikkuna: 12 months
|
Average Steady-State Concentration(Cav) |
12 months
|
|
Steady state pharmacokinetic parameter: Steady-State Clearance(CLss)
Aikaikkuna: 12 months
|
Steady-State Clearance(CLss) |
12 months
|
|
PK exposure parameter :Maximum Steady-State Concentration(Cmax,ss)
Aikaikkuna: 12 months
|
Maximum Steady-State Concentration(Cmax,ss) |
12 months
|
|
PK exposure parameter : Minimum Steady-State Concentration(Cmin,ss)
Aikaikkuna: 12 months
|
Minimum Steady-State Concentration(Cmin,ss) |
12 months
|
|
PK exposure parameter : Trough Concentration(Ctrough)
Aikaikkuna: 12 months
|
Trough Concentration(Ctrough) |
12 months
|
|
PK exposure parameter : Fluctuation Degree(DF)
Aikaikkuna: 12 months
|
Fluctuation Degree(DF) |
12 months
|
|
PK exposure parameter : Accumulation Ratio(Ra)
Aikaikkuna: 12 months
|
Accumulation Ratio(Ra) |
12 months
|
|
PK exposure parameter : Time to Maximum Concentration at Steady State(Tmax,ss)
Aikaikkuna: 12 months
|
Time to Maximum Concentration at Steady State(Tmax,ss) |
12 months
|
|
PK exposure parameter : Volume of Distribution Calculated from the Terminal Elimination Phase(Vz)
Aikaikkuna: 12 months
|
Volume of Distribution Calculated from the Terminal Elimination Phase(Vz) |
12 months
|
|
ORR by investigators
Aikaikkuna: every 6 week, up to 12 months
|
proportion of patients with a best overall response of complete response or partial response |
every 6 week, up to 12 months
|
|
Disease Control Rate (DCR)
Aikaikkuna: every 6 weeks, up to12 months
|
the percentage of patients who have a best overall response of CR or PR or SD |
every 6 weeks, up to12 months
|
|
Duration of Response (DoR)
Aikaikkuna: every 6 weeks, up to 12 months
|
proportion of patients with the time from the date of first documented response until the date of documented progression or death in the absence of disease progression |
every 6 weeks, up to 12 months
|
|
PFS
Aikaikkuna: every 6 weeks, up to 12 months
|
proportion of patients with the time from randomization until the date of objective disease progression or death |
every 6 weeks, up to 12 months
|
|
OS
Aikaikkuna: 24 months
|
proportion of patients with the time from randomization until the date of objective disease progression or death |
24 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Caicun Zhou, MD, Shanghai East Hospital
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .